Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOCRYST PHARMACEUTICALS INC Director's Dealing 2011

Mar 3, 2011

31868_dirs_2011-03-03_486da151-7177-40e0-8951-5daacfeaab54.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2011-03-01

Reporting Person: McCullough David (VP)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-03-01 Common Stock A 6000 Acquired 11626 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-03-01 Stock Option (Right to Buy) $4.15 A 40000 Acquired 2021-03-01 Common Stock (40000) Direct

Footnotes

F1: Restricted stock award. Will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

F2: Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.